Non-Small-Cell Lung Cancer | Current Treatment: Physician Insights | US | 2022
The current treatment armamentarium for non-small-cell lung cancer (NSCLC) is dominated by biomarker-driven therapies and immune checkpoint inhibitors. Therapeutic options in this indication have rapidly increased over the past years. In 2021, NSCLC witnessed the FDA approvals of Rybrevant, Exkivity, Libtayo, Tepmetko, and Lumakras. Notably, Amgen’s Lumakras is the first Kirsten rat sarcoma viral oncogene homolog (KRAS) inhibitor to have received a marketing authorization from the FDA, and it adds another actionable target to the growing list of relevant biomarkers in NSCLC, which includes EGFR, ALK, ROS1, RET, MET, BRAF, and KRAS. Established therapies such as AstraZeneca’s Tagrisso and Roche’s Tecentriq have seen label expansions to the adjuvant setting, improving treatment options for certain patients with early-stage disease.
Questions answered
- What are the treatment rates for metastatic NSCLC in the various lines of therapy?
- What are the testing rates for different biomarkers, and what is the uptake of key biomarker-driven therapies?
- How are the new entrants performing in the presence of existing therapies in the metastatic NSCLC setting?
- What are the main drivers for prescribing select therapies, and what are the key obstacles reported by surveyed physicians?
Product description
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States.
Primary research: Survey of 101 U.S. medical oncologists.
Key drugs covered:
Keytruda, Tecentriq, Opdivo, Yervoy, Imfinzi, Libtayo, Tagrisso, Rybrevant, Tarceva, Exkivity, Alecensa, Xalkori, Rozlytrek, Retevmo, Gavreto, Tabrecta, Tepmetko, Alimta, Lumakras.
